We obtained high-quality cardiac tissue-like constructs (CTLCs) by cultivating hiPSC-CMs on aligned nanofibers made of biodegradable polymer. We show that multi-layered and elongated CMs could promptly be organized at high density along aligned nanofibers, resulting in upregulated cardiac biomarkers and enhanced cardiac functions. When used for drug assessment, CTLCs were much more robust than the 2D conventional control. We used the CTLCs to simulate the repairing of disconnected and arrhythmia CMs in vitro. When used to repair injured rat hearts, the CTLCs showed excellent operability leading to favorable heart function recovery.
Researchers from the Institute for Integrated Cell-Material Sciences (iCeMS) of Kyoto University and the Department of Cardiovascular Surgery of Osaka University have developed effective and convenient Cardiac Tissue-Like Constructs (CTLCs) for repairing myocardial infarctions.
Cardiovascular diseases such as infarctions are the leading cause of death globally. A seriously injured heart cannot recover by itself, and heart transplants are the only effective treatment. However, the waiting list for transplants is extremely long. Previous researchers have also used cell transplant technologies to repair injured hearts, but these used CMs organized in two dimensions with a random, myofibril structure, which is different from natural heart tissue.
Dr. Li Liu and Prof. Yong Chen of iCeMS, together with Prof. Yoshiki Sawa of Osaka University and colleagues, selected a PLGA material approved by the FDA, and prepared biodegradable, aligned nanofibers for culturing CMs derived from hiPSCs, successfully creating organized and functional CTLCs.
They found that the CMs infiltrated and enveloped the nanofibers, showing elongation and high organization with upregulated expression of cardiac markers. Their CTLCs demonstrated more robust drug response compared with 2D CMs.
The team also used the CTLCs to simulate the repairing of disconnected and arrhythmia CMs. When used to repair injured rat hearts, the CTLCs showed excellent operability leading to favorable heart function recovery.
Future studies are now being planned to use CTLCs to repair injured hearts of larger animals, before advancing to clinical applications.
Learn more:Â Mending hearts in three dimensions
The Latest on: Repairing myocardial infarctions
- Abiomed's (ABMD) Impella-Related Research Gets FDA Clearanceon September 19, 2022 at 8:13 am
Abiomed, Inc. ABMD recently announced the receipt of two approvals from the FDA, which are related to clinical research of Impella heart pumps in acute myocardial infarction (AMI) cardiogenic shock ...
- Health Care in the 21st Centuryon September 14, 2022 at 5:00 pm
The physician diagnoses an evolving myocardial infarction by commanding ... in the left anterior descending coronary artery and repair it. The hospital transmits the computerized information ...
- Greater Cardiac Drug Use Tied to Lower Post-MI Mortality in Hemodialysis Populationon September 14, 2022 at 6:37 am
Suboptimal management of myocardial infarction in patients with kidney failure may be a key modifiable cause of the worse prognosis, according to investigators.
- Patient access to cardiology services—rather than cardiologists’ effectiveness—varies widely by regionon September 14, 2022 at 2:51 am
The report from the Institute for Fiscal Studies attributes different outcomes of treatment for myocardial infarction in England to the variable quality of cardiologists.12 Quality is assessed by ...
- Abiomed Wins 2 FDA Nods for Clinical Trialson September 13, 2022 at 5:00 pm
Abiomed announced two approvals from FDA related to clinical research of the Impella heart pumps in acute myocardial infarction (AMI ... winning a nod from FDA for the Pascal Precision valve repair ...
- Dedicated women’s heart centers can improve accurate diagnoseson September 8, 2022 at 2:12 am
Cardiac conditions in women are underdiagnosed, undertreated, and under-researched compared to men. Investigators report that attending a multidisciplinary dedicated women’s heart center can increase ...
- Cardior Announces CE Marking of CardiorHealth miR-132 PCR Kit Used in Ongoing HF-REVERT Phase 2 Clinical Studyon September 8, 2022 at 2:00 am
Cardior is developing CDR132L as a therapeutic candidate to improve cardiac systolic and diastolic function in patients with heart failure. By selectively blocking aberrant miR-132 levels, CDR132L has ...
- How a Certain Animal Can Regenerate a Broken Hearton September 6, 2022 at 11:47 am
Zebrafish may repair heart tissue after injury, according to research conducted by the MDC team under the direction of Jan Philipp Junker and Daniela Panáková. When a person has a heart attack and ...
- Technique Talk: Developing Spatial Multiomic Mapson August 29, 2022 at 11:17 am
Mapping the cell-type specific molecular changes in the tissue context after myocardial infarction allows researchers to identify regional tissue repair mechanisms in the human heart and guide novel ...
- Healthy people over 65 years of age recommended to get a heart check-up before non-cardiac surgeryon August 26, 2022 at 10:22 am
The aim is to prevent cardiovascular complications including myocardial infarction ... recommend surgical or transcatheter valve repair or balloon valvuloplasty as a bridge to repair.
via Google News and Bing News
